United States (National)
Not enough data
Benjamin P. Levy's coverage prominently focuses on healthcare and pharmaceuticals, particularly in the context of cancer treatment with a specific emphasis on NSCLC (non-small cell lung cancer), antibody-drug conjugates, biomarker testing, and gastric cancer.
Given this focus, he is likely to be most responsive to pitches that offer expert commentary from professionals deeply involved in the development or application of oncology treatments such as researchers, clinicians specializing in lung cancer treatment, pharmaceutical industry experts or patient advocates.
As Benjamin’s articles cite data extensively and delve into industry-specific details related to healthcare and biotechnology topics like clinical trials or drug developments, tailored pitches offering new research findings or insights into emerging treatments are more likely to resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Julia K. Rotow, Ross Camidge, Benjamin P. Levy, Siddhartha Devarakonda, Gilberto Lopes
Both liquid and tissue biopsies have roles in progression workup. Liquid biopsies offer rapid turnaround but cannot be trusted when negative due to false-negative rates.
By: Ross Camidge, Siddhartha Devarakonda, Gilberto Lopes, Julia K. Rotow, Benjamin P. Levy
Dr. Lopes analyzes the evidence hierarchy, noting stronger evidence for MARIPOSA-2 with over 600 patients in a fully-powered study versus COMPEL's under 100 patients in an early-stopped trial.
By: Robert Garrett, Benjamin P. Levy, Deepak L. Bhatt, Kevin Beiner, Stephanie Wierwille
In the latest video from our roundtable, healthcare leaders talk about the impact of insufficient reimbursements. They're posing more headaches for hospitals and affecting patient care, the panel says.
By: Siddhartha Devarakonda, Gilberto Lopes, Julia K. Rotow, Benjamin P. Levy, Ross Camidge
By: Julia K. Rotow, Benjamin P. Levy, Ross Camidge, Siddhartha Devarakonda, Gilberto Lopes
MET amplification detection uses FISH or next-generation sequencing with arbitrary copy number cutoffs (typically 6-10 copies) lacking scientific standardization.
By: Kevin Beiner, Deepak L. Bhatt, Stephanie Wierwille, Benjamin P. Levy, Robert Garrett
In the latest video from the Chief Healthcare Executive Roundtable, the panel discusses the difficulty in holding onto top talent, keeping workers healthy, and opportunities and challenges with AI.
By: Julia K. Rotow, Benjamin P. Levy, Siddhartha Devarakonda, D. Ross Camidge, Gilberto Lopes
Dr. Camidge predicts TROP2-directed ADCs will become obsolete due to poor tolerability profiles, while better-tolerated ADC platforms will emerge. He anticipates advances in understanding persistent cell populations preventing complete tumor eradication, potentially through surface marker-directed ADCs or radiopharmaceuticals. Pleural-based therapies represent another frontier, given recurrent pleural involvement in EGFR-mutant disease.
By: Ross Camidge, Siddhartha Devarakonda, Julia K. Rotow, Benjamin P. Levy, Gilberto Lopes
By: Stephanie Wierwille, Kevin Beiner, Deepak L. Bhatt, Benjamin P. Levy, Robert Garrett
Our panel of healthcare leaders outline the areas where AI is paying dividends, even as they acknowledge the need for caution.
By: Benjamin P. Levy, Robert Garrett, Deepak L. Bhatt, Stephanie Wierwille, Kevin Beiner
In the latest video from the Chief Healthcare Executive Roundtable, our panel talks about the need to be open with patients about the use of AI.
